| Title |
Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study
|
|---|---|
| Published in |
PLOS ONE, April 2012
|
| DOI | 10.1371/journal.pone.0035843 |
| Pubmed ID | |
| Authors |
Pietro Iaffaldano, Rosa Gemma Viterbo, Damiano Paolicelli, Guglielmo Lucchese, Emilio Portaccio, Benedetta Goretti, Vita Direnzo, Mariangela D'Onghia, Stefano Zoccolella, Maria Pia Amato, Maria Trojano |
| Abstract |
Natalizumab reduces the relapse rate and magnetic resonance imaging activity in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). So far the influence of natalizumab on cognitive functions and fatigue in MS remains uncertain. The aim of this prospective, open-label, observational study was to evaluate the possible effects of natalizumab on cognition and fatigue measures in RRMS patients treated for up to two years. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 2% |
| United Kingdom | 1 | 1% |
| Unknown | 92 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 20% |
| Researcher | 12 | 13% |
| Student > Master | 11 | 12% |
| Student > Bachelor | 7 | 7% |
| Student > Postgraduate | 6 | 6% |
| Other | 20 | 21% |
| Unknown | 20 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 34% |
| Neuroscience | 13 | 14% |
| Psychology | 8 | 8% |
| Economics, Econometrics and Finance | 2 | 2% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Other | 7 | 7% |
| Unknown | 31 | 33% |